REHVOW Trademark

Trademark Overview


On Thursday, September 20, 2018, a trademark application was filed for REHVOW with the United States Patent and Trademark Office. The USPTO has given the REHVOW trademark a serial number of 88125027. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 2, 2020. This trademark is owned by Eli Lilly and Company. The REHVOW trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, ulcer...
rehvow

General Information


Serial Number88125027
Word MarkREHVOW
Filing DateThursday, September 20, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 2, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 29, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, ulcerative colitis; Diagnostic agents and substances for medical purposes; Radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases and of oncology and of pain

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, September 26, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, November 2, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, November 2, 2020ABANDONMENT - NO USE STATEMENT FILED
Thursday, March 5, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 3, 2020EXTENSION 2 GRANTED
Tuesday, March 3, 2020EXTENSION 2 FILED
Tuesday, March 3, 2020TEAS EXTENSION RECEIVED
Saturday, July 27, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 25, 2019EXTENSION 1 GRANTED
Thursday, July 25, 2019EXTENSION 1 FILED
Thursday, July 25, 2019TEAS EXTENSION RECEIVED
Tuesday, March 26, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 29, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 29, 2019PUBLISHED FOR OPPOSITION
Wednesday, January 9, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, December 21, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, December 21, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, December 21, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, December 19, 2018ASSIGNED TO LIE
Tuesday, December 18, 2018ASSIGNED TO LIE
Thursday, December 13, 2018TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, November 5, 2018NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, November 5, 2018LETTER OF SUSPENSION E-MAILED
Monday, November 5, 2018SUSPENSION LETTER WRITTEN
Wednesday, October 31, 2018ASSIGNED TO EXAMINER
Wednesday, September 26, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, September 24, 2018NEW APPLICATION ENTERED IN TRAM